Scalper1 News
Biogen Idec (BIIB) soared nearly 10% to a new high Friday as its much-anticipated Alzheimer’s disease drug results surpassed Wall Street expectations. At a medical conference in France, Biogen reported the results of a phase 1b study in which 166 patients were divided into five groups, one a placebo group and the others taking different doses of Biogen’s drug candidate aducanumab, or BIIB-037. After 54 weeks, those in all but the lowest-dose group Scalper1 News
Scalper1 News